25-08-2022, 09:26 AM
“There are more questions than answers,” Myron Cohen, MD, director of the University of North Carolina Institute for Global Health & Infectious Diseases in Chapel Hill and a leader of the National Institutes of Health’s COVID-19 Prevention Network, noted in an interview.
Rebound isn’t even mentioned in the article that in April reported results from the EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial, which was the basis of Paxlovid’s EUA.
https://jamanetwork.com/journals/jama/fu...le/2793357
Rebound isn’t even mentioned in the article that in April reported results from the EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial, which was the basis of Paxlovid’s EUA.
https://jamanetwork.com/journals/jama/fu...le/2793357